Cargando…

Dynamics of success and failure in phage and antibiotic therapy in experimental infections

BACKGROUND: In 1982 Smith and Huggins showed that bacteriophages could be at least as effective as antibiotics in preventing mortality from experimental infections with a capsulated E. coli (K1) in mice. Phages that required the K1 capsule for infection were more effective than phages that did not r...

Descripción completa

Detalles Bibliográficos
Autores principales: Bull, J J, Levin, Bruce R, DeRouin, Terry, Walker, Nina, Bloch, Craig A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138797/
https://www.ncbi.nlm.nih.gov/pubmed/12453306
http://dx.doi.org/10.1186/1471-2180-2-35
_version_ 1782120495232057344
author Bull, J J
Levin, Bruce R
DeRouin, Terry
Walker, Nina
Bloch, Craig A
author_facet Bull, J J
Levin, Bruce R
DeRouin, Terry
Walker, Nina
Bloch, Craig A
author_sort Bull, J J
collection PubMed
description BACKGROUND: In 1982 Smith and Huggins showed that bacteriophages could be at least as effective as antibiotics in preventing mortality from experimental infections with a capsulated E. coli (K1) in mice. Phages that required the K1 capsule for infection were more effective than phages that did not require this capsule, but the efficacies of phages and antibiotics in preventing mortality both declined with time between infection and treatment, becoming virtually ineffective within 16 hours. RESULTS: We develop quantitative microbiological procedures that (1) explore the in vivo processes responsible for the efficacy of phage and antibiotic treatment protocols in experimental infections (the Resistance Competition Assay, or RCA), and (2) survey the therapeutic potential of phages in vitro (the Phage Replication Assay or PRA). We illustrate the application and utility of these methods in a repetition of Smith and Huggins' experiments, using the E. coli K1 mouse thigh infection model, and applying treatments of phages or streptomycin. CONCLUSIONS: 1) The Smith and Huggins phage and antibiotic therapy results are quantitatively and qualitatively robust. (2) Our RCA values reflect the microbiological efficacies of the different phages and of streptomycin in preventing mortality, and reflect the decline in their efficacy with a delay in treatment. These results show specifically that bacteria become refractory to treatment over the term of infection. (3) The K1-specific and non-specific phages had similar replication rates on bacteria grown in broth (based on the PRA), but the K1-specific phage had markedly greater replication rates in mouse serum.
format Text
id pubmed-138797
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1387972002-12-19 Dynamics of success and failure in phage and antibiotic therapy in experimental infections Bull, J J Levin, Bruce R DeRouin, Terry Walker, Nina Bloch, Craig A BMC Microbiol Research Article BACKGROUND: In 1982 Smith and Huggins showed that bacteriophages could be at least as effective as antibiotics in preventing mortality from experimental infections with a capsulated E. coli (K1) in mice. Phages that required the K1 capsule for infection were more effective than phages that did not require this capsule, but the efficacies of phages and antibiotics in preventing mortality both declined with time between infection and treatment, becoming virtually ineffective within 16 hours. RESULTS: We develop quantitative microbiological procedures that (1) explore the in vivo processes responsible for the efficacy of phage and antibiotic treatment protocols in experimental infections (the Resistance Competition Assay, or RCA), and (2) survey the therapeutic potential of phages in vitro (the Phage Replication Assay or PRA). We illustrate the application and utility of these methods in a repetition of Smith and Huggins' experiments, using the E. coli K1 mouse thigh infection model, and applying treatments of phages or streptomycin. CONCLUSIONS: 1) The Smith and Huggins phage and antibiotic therapy results are quantitatively and qualitatively robust. (2) Our RCA values reflect the microbiological efficacies of the different phages and of streptomycin in preventing mortality, and reflect the decline in their efficacy with a delay in treatment. These results show specifically that bacteria become refractory to treatment over the term of infection. (3) The K1-specific and non-specific phages had similar replication rates on bacteria grown in broth (based on the PRA), but the K1-specific phage had markedly greater replication rates in mouse serum. BioMed Central 2002-11-26 /pmc/articles/PMC138797/ /pubmed/12453306 http://dx.doi.org/10.1186/1471-2180-2-35 Text en Copyright © 2002 Bull et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research Article
Bull, J J
Levin, Bruce R
DeRouin, Terry
Walker, Nina
Bloch, Craig A
Dynamics of success and failure in phage and antibiotic therapy in experimental infections
title Dynamics of success and failure in phage and antibiotic therapy in experimental infections
title_full Dynamics of success and failure in phage and antibiotic therapy in experimental infections
title_fullStr Dynamics of success and failure in phage and antibiotic therapy in experimental infections
title_full_unstemmed Dynamics of success and failure in phage and antibiotic therapy in experimental infections
title_short Dynamics of success and failure in phage and antibiotic therapy in experimental infections
title_sort dynamics of success and failure in phage and antibiotic therapy in experimental infections
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138797/
https://www.ncbi.nlm.nih.gov/pubmed/12453306
http://dx.doi.org/10.1186/1471-2180-2-35
work_keys_str_mv AT bulljj dynamicsofsuccessandfailureinphageandantibiotictherapyinexperimentalinfections
AT levinbrucer dynamicsofsuccessandfailureinphageandantibiotictherapyinexperimentalinfections
AT derouinterry dynamicsofsuccessandfailureinphageandantibiotictherapyinexperimentalinfections
AT walkernina dynamicsofsuccessandfailureinphageandantibiotictherapyinexperimentalinfections
AT blochcraiga dynamicsofsuccessandfailureinphageandantibiotictherapyinexperimentalinfections